Advertisement

Neurochemical Research

, Volume 34, Issue 4, pp 707–710 | Cite as

Therapeutic Strategy for Ischemic Stroke

  • Toru Yamashita
  • Kentaro Deguchi
  • Yoshihide Sehara
  • Violeta Lukic-Panin
  • Hanzhe Zhang
  • Tatsushi Kamiya
  • Koji Abe
Original Paper

Abstract

Possible strategies for treating ischemic stroke include: (1) Neuroprotection: preventing damaged neurons from undergoing apoptosis in the acute phase of cerebral ischemia; (2) Stem cell therapy: the repair of broken neuronal networks with newly born neurons in the chronic phase of cerebral ischemia. Firstly, we studied the neuroprotective effect of a calcium channel blocker, azelnidipine, or a by-product of heme degradation, biliverdin, in the ischemic brain. These results revealed both azelnidipine and biliverdin had a neuroprotective effect in the ischemic brain through their anti-oxidative property. Secondly, we investigated the role of granulocyte colony-stimulating factor (G-CSF) by administering G-CSF to rats after cerebral ischemia and found G-CSF plays a critical role in neuroprotection. Lastly, we developed a restorative stroke therapy with a bio-affinitive scaffold, which is able to provide an appropriate environment for newly born neurons. In the future, we will combine these strategies to develop more effective therapies for treatment of strokes.

Keywords

Cerebral ischemia Free radical G-CSF Neural stem cells Scaffold 

Introduction

Strokes are a major cause of death and the reduction in the quality of life caused by a stroke is a serious problem for which effective therapy is not yet available. A new strategy for patients who have suffered a stroke is thus urgently required. Possible new strategies for treating ischemic strokes are broadly categorized into two groups: (1) neuroprotection, which prevents damaged neurons from undergoing apoptosis in the acute phase of stroke, and (2) stem cell therapy, which allows for the repair of disrupted neuronal networks of newly born neurons in the chronic phase of stroke [1]. In this paper, we focus on free radical scavengers and cytokines for neuroprotection, and on a bio-affinitive scaffold supporting neurosupplementation (Fig. 1).
Fig. 1

Therapeutic strategy against ischemic stroke. Increase of cerebral blood flow (CBF) and primary neuroprotection, in which both G-CSF and IL-6 play an important role for essential neuroprotection. On the other hand, the stem cell therapy is composed of two tactics: (1) activation of intrinsic neural stem cells, whose principal origin is the subventricular zone, and (2) transplantation of extrinsic neural stem cells. An appropriate scaffold is able to support this therapy

Free Radical Scavengers

Plenty of free radicals are generated during an ischemic stroke. These can peroxidize lipid, protein, and DNA in various brain cells, and have been implicated in the pathogenesis of cerebral infarction [2]. Thus, free radicals are regarded as an important therapeutic target for improving the outcome of an ischemic stroke. Recent studies using an animal model have reported that brain ischemic injury was ameliorated by using several free radical scavengers such as 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid; Trolox [3], 2,2,5,7,8-pentamethyl-6-hydroxychromane; PMC [4], disodium 4-[(tert-butylimino)-methyl]benzene-1,3-disulfonate N-oxide; NXY-059 [5], and 3-methyl-1-phenyl-2-pyrazolin-5-one; MCI-186 [6]. In large clinical trials in human, NXY-059 initially showed a reduction in disability following a stroke (SAINT I) [7], but eventually failed to represent the initial effect (SAINT II) [8]. In contrast, we originally reported that MCI-186 ameliorated brain edema in the ischemic brain [6], and has already been applied for a human clinical setting in Japan, and shown the effect of reducing the disability in stroke patients [9]. Recently we have sought new free radical scavengers, especially from preexisting drugs applied for different diseases (e.g., calcium channel blockers (CCBs) for hypertension) or endogenous effectors which humans originally possess (e.g., biliverdin), because these are expected to be applied as clinical drugs in the near future.

Several CCBs have a dihydropyridine ring which can reduce oxidative stress [10]. In order to clarify whether CCBs have an antioxidative property against cerebral ischemia, we treated Wistar rats with a CCB, azelnidipine (1 mg/kg), subjected the rats to 90-min MCAO, and investigated its effects on infarct volume and the oxidative damage. Treatment with azelnizipine reduced infarct volume and brain edema, compared with the vehicle. The expression of oxidative stress markers, such as HEL, 4-HNE, AGE, and 8-OHdG, were significantly decreased in the azelnizipine-treated group. These results suggested that azelnizipine had a neuroprotective effect in the ischemic brain, which came from, at least in part, its anti-oxidative property [11].

Biliverdin, one of the by-products of heme degradation, is also known to possess a cytoprotective effect against oxidative stress [12]. To estimate the effect of bilverdin on ischemic injury, biliverdin or vehicle was administered intraperioneally after 90-min MCAO. Biliverdin treatment significantly reduced infarct volume of the cerebral cortices. Ethidium staining at 4 h after MCAO revealed that superoxide production in the cerebral cortex was significantly reduced in the biliverdin-treated group. Moreover, biliverdin treatment decreased the number of stained cells for oxidative injury markers, 4-HNE and 8-OHdG. These results indicated that biliverdin-administration ameliorated ischemic brain injury through anti-oxidant mechanism [13].

Cytokines

The results of previous studies have suggested that the inflammatory reaction plays an important role in contributing to the pathophysiology of ischemia [14, 15, 16]. Thus, we have been interested in inflammatory cytokines such as IL-6 [17] and G-CSF, as effective candidates for neuroprotection.

To confirm the neuroprotective effect of G-CSF in ischemic injury, we injected G-CSF to rats immediately after 90-min transient MCAO. The 2, 3, 5-Triphenyltetrazolium chloride (TTC) staining of brain sections obtained at 72 h after MCAO showed a significant reduction of infarct volume in the G-CSF-treated group (Fig. 2). We also observed that the expression of TNF-α, TGF-β, and iNOS were significantly decreased in the G-CSF-treated group, indicating that the suppression of cytokines and iNOS may be implicated in the neuroprotecitive effect of G-CSF [18]. G-CSF has been applied for idiopathic or chemotherapy-induced neutropenia and related indications such as bone-marrow harvesting, and seems to be a well tolerated drug [19]. Moreover, G-CSF can be administrated to patients subcutaneously. Therefore, we regard G-CSF as a promising candidate for treating ischemic brain damage.
Fig. 2

G-CSF-treatment reduced infarct volume after MCAO. (a) Coronal sections stained with TTC obtained at 72 h after the MCAO. Scale bar, 2 mm. (b) Statistical analysis showed a significant decrease of the infarct volume in the G-CSF group 72 h after MCAO, compared to the vehicle group. Data are means ± SD. **P < 0.01, a two-tailed Student’s t-test

Stem Cell Therapy

To supply new neurons into the damaged brain after a stroke, two tactics are proposed. One is the activation of intrinsic neural stem cells [20, 21, 22]. The other is the transplantation of extrinsic neural stem cells [23] (Fig. 1). Recent studies reported the scaffold to be important for intrinsic or extrinsic stem cells to survive in necrotic brain tissue forming a cavity after brain injury [24, 25, 26]. We thus studied scaffolds by providing an appropriate environment to stem cells, and developed new methods using a new porous gelatin–siloxane hybrid derived from the integration of gelatin and 3-(glycidoxypropyl) trimethoxysilane [27]. This porous hybrid implanted into a defective part of the cerebral cortex and maintained at the same site for 60 days retained the integrity of the brain’s shape, and attached well to the surrounding brain tissues. Marginal cavities of the scaffolds remained occupied by newly formed tissue in the brain, where newly produced endothelial, astroglial, and microglial cells were observed with bromodeoxyuridine double positivity. In addition, those cells increased in a dose-dependent manner following the addition of basic fibroblast growth factor (bFGF) and epidermal growth factor (EGF) [1, 28]. These results suggest that this new porous gelatin–siloxane hybrid has biocompatibility after implantation into a lesion of the central nervous system, and thus provided a potential scaffold for cell migration and angiogenesis with dose-dependent effects following the addition of bFGF and EGF.

In this paper, we briefly highlighted our recent progress in the development of these distinct new strategies for the treatment of damaged brains following a stroke. To realize more effective therapies for patients who have suffered a stroke, it is important to combine these strategies in the acute or chronic phase following a stroke.

References

  1. 1.
    Abe K (2000) Therapeutic potential of neurotrophic factors and neural stem cells against ischemic brain injury. J Cereb Blood Flow Metab 20:1393–1408. doi: 10.1097/00004647-200010000-00001 PubMedCrossRefGoogle Scholar
  2. 2.
    Chan PH (2001) Reactive oxygen radicals in signaling and damage in the ischemic brain. J Cereb Blood Flow Metab 21:2–14. doi: 10.1097/00004647-200101000-00002 PubMedCrossRefGoogle Scholar
  3. 3.
    Sharma SS, Kaundal RK (2007) Neuroprotective effects of 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid (Trolox), an antioxidant in middle cerebral artery occlusion induced focal cerebral ischemia in rats. Neurol Res 29:304–309. doi: 10.1179/016164107X158983 PubMedCrossRefGoogle Scholar
  4. 4.
    Hsiao G, Lee JJ, Chen YC et al (2007) Neuroprotective effects of PMC, a potent alpha-tocopherol derivative, in brain ischemia-reperfusion: reduced neutrophil activation and anti-oxidant actions. Biochem Pharmacol 73:682–693. doi: 10.1016/j.bcp.2006.11.009 PubMedCrossRefGoogle Scholar
  5. 5.
    Kuroda S, Tsuchidate R, Smith ML et al (1999) Neuroprotective effects of a novel nitrone, NXY-059, after transient focal cerebral ischemia in the rat. J Cereb Blood Flow Metab 19:778–787. doi: 10.1097/00004647-199907000-00008 PubMedCrossRefGoogle Scholar
  6. 6.
    Abe K, Yuki S, Kogure K (1988) Strong attenuation of ischemic and postischemic brain edema in rats by a novel free radical scavenger. Stroke 19:480–485PubMedGoogle Scholar
  7. 7.
    Lees KR, Zivin JA, Ashwood T et al (2006) NXY-059 for acute ischemic stroke. N Engl J Med 354:588–600. doi: 10.1056/NEJMoa052980 PubMedCrossRefGoogle Scholar
  8. 8.
    Shuaib A, Lees KR, Lyden P et al (2007) NXY-059 for the treatment of acute ischemic stroke. N Engl J Med 357:562–571. doi: 10.1056/NEJMoa070240 PubMedCrossRefGoogle Scholar
  9. 9.
    The Edaravone Acute Brain Infarction Study Group (2003) Effect of a novel free radical scavenger, edaravone (MCI-186), on acute brain infarction. Randomized, placebo-controlled, double-blind study at multicenters. Cerebrovasc Dis 15:222–229. doi: 10.1159/000069318 CrossRefGoogle Scholar
  10. 10.
    Yao K, Ina Y, Nagashima K et al (2000) Antioxidant effects of calcium antagonists in rat brain homogenates. Biol Pharm Bull 23:766–769PubMedGoogle Scholar
  11. 11.
    Lukic-Panin V, Kamiya T, Zhang H et al (2007) Prevention of neuronal damage by calcium channel blockers with antioxidative effects after transient focal ischemia in rats. Brain Res 1176:143–150. doi: 10.1016/j.brainres.2007.07.038 PubMedCrossRefGoogle Scholar
  12. 12.
    Stocker R (2004) Antioxidant activities of bile pigments. Antioxid Redox Signal 6:841–849PubMedGoogle Scholar
  13. 13.
    Deguchi K, Hayashi T, Nagotani S et al (2008) Reduction of cerebral infarction in rats by biliverdin associated with amelioration of oxidative stress. Brain Res 1188:1–8. doi: 10.1016/j.brainres.2007.07.104 PubMedCrossRefGoogle Scholar
  14. 14.
    Iadecola C, Alexander M (2001) Cerebral ischemia and inflammation. Curr Opin Neurol 14:89–94. doi: 10.1097/00019052-200102000-00014 PubMedCrossRefGoogle Scholar
  15. 15.
    Loddick SA, Rothwell NJ (1996) Neuroprotective effects of human recombinant interleukin-1 receptor antagonist in focal cerebral ischaemia in the rat. J Cereb Blood Flow Metab 16:932–940. doi: 10.1097/00004647-199609000-00017 PubMedCrossRefGoogle Scholar
  16. 16.
    Yang GY, Schielke GP, Gong C et al (1999) Expression of tumor necrosis factor-alpha and intercellular adhesion molecule-1 after focal cerebral ischemia in interleukin-1beta converting enzyme deficient mice. J Cereb Blood Flow Metab 19:1109–1117. doi: 10.1097/00004647-199910000-00007 PubMedCrossRefGoogle Scholar
  17. 17.
    Yamashita T, Sawamoto K, Suzuki S et al (2005) Blockade of interleukin-6 signaling aggravates ischemic cerebral damage in mice: possible involvement of Stat3 activation in the protection of neurons. J Neurochem 94:459–468. doi: 10.1111/j.1471-4159.2005.03227.x PubMedCrossRefGoogle Scholar
  18. 18.
    Sehara Y, Hayashi T, Deguchi K et al (2007) Decreased focal inflammatory response by G-CSF may improve stroke outcome after transient middle cerebral artery occlusion in rats. J Neurosci Res 85:2167–2174. doi: 10.1002/jnr.21341 PubMedCrossRefGoogle Scholar
  19. 19.
    Schneider A, Kuhn HG, Schabitz WR (2005) A role for G-CSF (granulocyte-colony stimulating factor) in the central nervous system. Cell Cycle 4:1753–1757PubMedGoogle Scholar
  20. 20.
    Nakatomi H, Kuriu T, Okabe S et al (2002) Regeneration of hippocampal pyramidal neurons after ischemic brain injury by recruitment of endogenous neural progenitors. Cell 110:429–441. doi: 10.1016/S0092-8674(02)00862-0 PubMedCrossRefGoogle Scholar
  21. 21.
    Teramoto T, Qiu J, Plumier JC et al (2003) EGF amplifies the replacement of parvalbumin-expressing striatal interneurons after ischemia. J Clin Invest 111:1125–1132PubMedGoogle Scholar
  22. 22.
    Yamashita T, Ninomiya M, Hernandez Acosta P et al (2006) Subventricular zone-derived neuroblasts migrate and differentiate into mature neurons in the post-stroke adult striatum. J Neurosci 26:6627–6636. doi: 10.1523/JNEUROSCI.0149-06.2006 PubMedCrossRefGoogle Scholar
  23. 23.
    Hayashi J, Takagi Y, Fukuda H et al (2006) Primate embryonic stem cell-derived neuronal progenitors transplanted into ischemic brain. J Cereb Blood Flow Metab 26(7):906–914PubMedCrossRefGoogle Scholar
  24. 24.
    Hou S, Xu Q, Tian W et al (2005) The repair of brain lesion by implantation of hyaluronic acid hydrogels modified with laminin. J Neurosci Methods 148:60–70. doi: 10.1016/j.jneumeth.2005.04.016 PubMedCrossRefGoogle Scholar
  25. 25.
    Kataoka K, Suzuki Y, Kitada M et al (2001) Alginate, a bioresorbable material derived from brown seaweed, enhances elongation of amputated axons of spinal cord in infant rats. J Biomed Mater Res 54:373–384. doi :10.1002/1097-4636(20010305)54:3<373::AID-JBM90>3.0.CO;2-QGoogle Scholar
  26. 26.
    Tian WM, Hou SP, Ma J et al (2005) Hyaluronic acid-poly-d-lysine-based three-dimensional hydrogel for traumatic brain injury. Tissue Eng 11:513–525. doi: 10.1089/ten.2005.11.513 PubMedCrossRefGoogle Scholar
  27. 27.
    Ren L, Tsuru K, Hayakawa S et al (2002) Novel approach to fabricate porous gelatin-siloxane hybrids for bone tissue engineering. Biomaterials 23:4765–4773. doi: 10.1016/S0142-9612(02)00226-0 PubMedCrossRefGoogle Scholar
  28. 28.
    Deguchi K, Tsuru K, Hayashi T et al (2006) Implantation of a new porous gelatin-siloxane hybrid into a brain lesion as a potential scaffold for tissue regeneration. J Cereb Blood Flow Metab 26(10):1263–1273PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Toru Yamashita
    • 1
  • Kentaro Deguchi
    • 1
  • Yoshihide Sehara
    • 1
  • Violeta Lukic-Panin
    • 1
  • Hanzhe Zhang
    • 1
  • Tatsushi Kamiya
    • 1
  • Koji Abe
    • 1
  1. 1.Department of Neurology, Graduate School of Medicine, Dentistry and Pharmaceutical SciencesOkayama UniversityOkayamaJapan

Personalised recommendations